Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 8/20 | 0.68 |
| ▸ | DDB1 | Q16531 | 6/20 | 0.68 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.67 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.67 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.67 |
| ▸ | NCOR2 | Q9Y618 | 4/20 | 0.67 |
| ▸ | STAT3 | P40763 | 2/20 | 0.65 |
| ▸ | CA2 | P00918 | 2/20 | 0.59 |
| ▸ | MIF | P14174 | 3/20 | 0.58 |
| ▸ | BCL2 | P10415 | 3/20 | 0.58 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30869200 | 1.00 | CRBN (0.68) | CRBNDDB1HDAC3HDAC1HDAC2 | |
| SCHEMBL22325167 | 1.00 | CRBN (0.68) | CRBNDDB1HDAC3HDAC1HDAC2 | |
| SCHEMBL20242290 | 1.00 | CRBN (0.68) | CRBNDDB1HDAC3HDAC1HDAC2 | |
| SCHEMBL20142514 | 1.00 | CRBN (0.68) | CRBNDDB1HDAC3HDAC1HDAC2 | |
| SCHEMBL30189563 | 1.00 | CRBN (0.68) | CRBNDDB1HDAC3HDAC1HDAC2 | |
| SCHEMBL20242552 | 1.00 | CRBN (0.68) | CRBNDDB1HDAC3HDAC1HDAC2 | |
| SCHEMBL22326316 | 1.00 | CRBN (0.68) | CRBNDDB1HDAC3HDAC1HDAC2 | |
| SCHEMBL22834201 | 1.00 | CRBN (0.68) | CRBNDDB1HDAC3HDAC1HDAC2 | |
| SCHEMBL21179283 | 0.99 | CRBN (0.69) | CRBNDDB1HDAC3HDAC1HDAC2 | |
| SCHEMBL30189483 | 0.99 | CRBN (0.69) | CRBNDDB1HDAC3HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12552775-B2 | Compounds and uses thereof | FOGHORN THERAPEUTICS INC. (US) | 2026-02-17 | — | — | US | disclosed |
| US-20260027217-A1 | DEGRADERS THAT TARGET ALK AND THERAPEUTIC USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2026-01-29 | — | — | US | disclosed |
| US-12384776-B2 | Compounds and uses thereof | FOGHORN THERAPEUTICS INC. (US) | 2025-08-12 | — | — | US | disclosed |
| EP-3762381-B1 | BIVALENT AGENTS COMPRISING A SERINE THREONINE KINASE (AKT) LIGAND COVALENTLY LINKED TO A DEGRADATION/DISRUPTION MOIETY FOR THE TREATMENT OF CANCER | ICAHN SCHOOL MED MOUNT SINAI (US) | 2025-05-07 | — | — | EP | disclosed |
| US-12233128-B2 | Degraders that target ALK and therapeutic uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2025-02-25 | — | — | US | disclosed |
| CN-115666575-B | Compounds and uses thereof | 福宏治疗公司 | 2024-12-10 | — | — | CN | disclosed |
| EP-3856192-B1 | DEGRADERS THAT TARGET ALK AND THERAPEUTIC USES THEREOF | DANA FARBER CANCER INST INC (US) | 2024-09-11 | — | — | EP | disclosed |
| CN-116888108-B | Novel EGFR degradation agent | 上海齐鲁制药研究中心有限公司 | 2024-04-19 | — | — | CN | disclosed |
| US-20240101534-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2024-03-28 | — | — | US | disclosed |
| US-20230348452-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-11-02 | — | — | US | disclosed |
| WO-2021083949-A1 | BIFUNCTIONAL COMPOUNDS FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2021-05-06 | — | — | WO | disclosed |
| EP-3762381-A1 | SERINE THREONINE KINASE (AKT) DEGRADATION / DISRUPTION COMPOUNDS AND METHODS OF USE | Icahn School of Medicine at Mount Sinai (US) | 2021-01-13 | — | — | EP | disclosed |
| US-20200399266-A1 | SERINE THREONINE KINASE (AKT) DEGRADATION / DISRUPTION COMPOUNDS AND METHODS OF USE | ICAHN SCHOOL MED MOUNT SINAI (US) | 2020-12-24 | — | — | US | disclosed |
| US-20200399266-A1 | SERINE THREONINE KINASE (AKT) DEGRADATION / DISRUPTION COMPOUNDS AND METHODS OF USE | ICAHN SCHOOL MED MOUNT SINAI (US) | 2020-12-24 | — | — | US | disclosed |
| WO-2020163823-A2 | THERAPEUTIC AGENTS AND METHODS OF TREATMENT | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2020-08-13 | — | — | WO | disclosed |
| WO-2020160196-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2020-08-06 | — | — | WO | disclosed |
| WO-2020160196-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2020-08-06 | — | — | WO | disclosed |
| WO-2020069106-A1 | DEGRADERS THAT TARGET ALK AND THERAPEUTIC USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-04-02 | — | — | WO | disclosed |
| WO-2019173516-A1 | SERINE THREONINE KINASE (AKT) DEGRADATION / DISRUPTION COMPOUNDS AND METHODS OF USE | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2019-09-12 | — | — | WO | disclosed |
| WO-2019173516-A1 | SERINE THREONINE KINASE (AKT) DEGRADATION / DISRUPTION COMPOUNDS AND METHODS OF USE | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2019-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260027217-A1 | DEGRADERS THAT TARGET ALK AND THERAPEUTIC USES THEREOF | ALK, IGF1R, PDGFRB | CRBN 563/4885DDB1 3876/4885HDAC3 3344/4885 |
| US-20240101534-A1 | COMPOUNDS AND USES THEREOF | VHL, CLN6, BRCA1 | CRBN 163/4885DDB1 576/4885HDAC3 281/4885 |
| US-12552775-B2 | Compounds and uses thereof | SMARCC1, SMARCC2, CHD1 | CRBN 125/4885DDB1 484/4885HDAC3 102/4885 |
| US-12384776-B2 | Compounds and uses thereof | VHL, TFEB, BECN1 | CRBN 74/4885DDB1 706/4885HDAC3 269/4885 |
| US-12233128-B2 | Degraders that target ALK and therapeutic uses thereof | ALK, BCR, IDE | CRBN 124/4885DDB1 1999/4885HDAC3 1711/4885 |
| US-20200399266-A1 | SERINE THREONINE KINASE (AKT) DEGRADATION / DISRUPTION COMPOUNDS AND METHODS OF USE | MKNK1, MKNK2, MTOR | CRBN 527/4885DDB1 1141/4885HDAC3 1092/4885 |
| US-20230348452-A1 | COMPOUNDS AND USES THEREOF | VHL, CLN6, BRCA1 | CRBN 163/4885DDB1 576/4885HDAC3 281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.